Pacific Biosciences of California (PACB) vs 10x Genomics (TXG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
10x Genomics (TXG) has outperformed Pacific Biosciences of California (PACB) over the past year, gaining 556.0% versus a gain of 94.3%. Over five years, TXG leads with a -50.0% price change compared with -88.8% for PACB. 10x Genomics is the larger company by market cap ($9.92 billion vs $845.5 million), about 11.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PACB | TXG |
|---|---|---|
| Share price | $2.72 | $76.10 |
| Market cap | $845.46M | $9.92B |
| 1-day change | +0.74% | -5.65% |
| YTD return | +45.45% | +366.58% |
| 1-year return | +94.29% | +556.03% |
| 5-year return | -88.85% | -50.02% |
| Forward P/E | — | 992.57 |
| EPS (TTM) | $-0.43 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $642.82M |
| Revenue growth (YoY) | — | +5.25% |
| Net income (latest FY) | — | $-43.54M |
| Gross margin | — | 69.05% |
| Operating margin | — | -9.49% |
| Net margin | — | -6.77% |
| 52-week high | $3.44 | $102.81 |
| 52-week low | $1.07 | $11.16 |
| Distance from 52-week high | -20.93% | -25.98% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | -13.27% |
| Average volume | 9.85M | 3.15M |
| Shares outstanding | 310.83M | 120.21M |
| Employees | — | 1,178 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- 10x Genomics is about 11.7 times larger than Pacific Biosciences of California by market value ($9.92B vs $845.46M).
- TXG has outperformed PACB by 461.7 percentage points over the past year.
About 10x Genomics
TXG stock →10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.
Industrials · Biotechnology: Laboratory Analytical Instruments · 1,178 employees
PACB vs TXG FAQ
Which is bigger, Pacific Biosciences of California or 10x Genomics?
10x Genomics (TXG) is larger, with a market capitalization of $9.92B compared with $845.46M for Pacific Biosciences of California (PACB).
Which stock has performed better over the past year, PACB or TXG?
TXG returned +556.03% over the past 12 months, compared with +94.29% for PACB (price return, excluding dividends). Past performance does not predict future results.
Are Pacific Biosciences of California and 10x Genomics in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.